## **Supplementary Appendix**

**Manuscript:** Hydroxychloroquine for prevention of COVID-19 mortality: a population-based cohort study

**Open source materials:** All code for data management and analyses and raw outputs are openly shared online for review and re-use (<u>https://github.com/opensafely/hydroxychloroquine-research</u>). All iterations of the pre-specified study protocol are archived with version control (<u>https://github.com/opensafely/hydroxychloroquine-research/tree/master/protocol</u>).

#### **Table of Contents**

| Information governance and ethics  | 2  |
|--|----|
| Patient and public involvement   | 2  |
| eFigure 1. Study diagram   | 3  |
| eFigure 2. Directed acyclic graph  | 4  |
| eTable 1. Demographic and clinical characteristics of 167,874 patients with rheumatoid arthritis                     | 5  |
| <b>eTable 2.</b> Demographic and clinical characteristics of 26,763 patients with systemic lupus erythematosus (SLE) | 7  |
| eTable 3. Interactions with HCQ use on the risk of COVID-19 mortality  | 9  |
| <b>eTable 4.</b> Sensitivity analyses of the association between HCQ use and the risk of COVID-19 mortality          | 11 |
| eTable 5. Bias-adjusted associations using a range of estimated prevalence of biologic DMARD                         | S  |
| and associations with COVID-19 mortality   | 12 |
| eTable 6. Comparison of estimates between stratified Cox proportional hazards models and                             |    |
| Royston-Parmar flexible parametric models  | 13 |
| Estimating prevalence of biologic DMARDs by exposure group for eTable 5  | 14 |
| References   | 15 |

### Information governance and ethics

NHS England is the data controller; TPP is the data processor; and the key researchers on OpenSAFELY are acting on behalf of NHS England. OpenSAFELY is hosted within the TPP environment which is accredited to the ISO 27001 information security standard and is NHS IG Toolkit compliant;<sup>1,2</sup> patient data are pseudonymised for analysis and linkage using industry standard cryptographic hashing techniques; all pseudonymised datasets transmitted for linkage onto OpenSAFELY are encrypted; access to the platform is via a virtual private network (VPN) connection, restricted to a small group of researchers who hold contracts with NHS England and only access the platform to initiate database queries and statistical models. All database activity is logged; only aggregate statistical outputs leave the platform environment following best practice for anonymisation of results such as statistical disclosure control for low cell counts.<sup>3</sup> The OpenSAFELY platform adheres to the data protection principles of the UK Data Protection Act 2018 and the EU General Data Protection Regulation (GDPR) 2016. In March 2020, the Secretary of State for Health and Social Care used powers under the UK Health Service (Control of Patient Information) Regulations 2002 (COPI) to require organisations to process confidential patient information for the purposes of protecting public health, providing healthcare services to the public and monitoring and managing the COVID-19 outbreak and incidents of exposure.<sup>4</sup> Taken together, these provide the legal bases to link patient datasets on the OpenSAFELY platform. This study was approved by the Health Research Authority (REC reference 20/LO/0651) and by the LSHTM Ethics Board (ref 21863).

## Patient and public involvement

Patients were not formally involved in developing this specific study design that was developed rapidly in the context of a global health emergency. We have developed a publicly available website <a href="https://opensafely.org/">https://opensafely.org/</a> through which we invite any patient or member of the public to contact us regarding this study or the broader OpenSAFELY project.

#### eFigure 1. Study diagram



Time

Index date (1 March 2020)

End of follow-up

Abbreviations: STP, Sustainability and Transformation Partnership (a National Health Service administrative region); sDMARD, synthetic disease-modifying antirheumatic drug; IMD, index of multiple deprivation; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; COVID-19, coronavirus disease 2019; Notes: End of follow-up was earliest of: date of death, seven days prior to last date of Office of National Statistics mortality data to account for reporting lag, or date of first hydroxychloroquine prescription on or after index date (for patients without hydroxychloroquine use at index date)



# eFigure 2. Directed acyclic graph

Minimal adjustment set: age, sex, ethnicity, geographic region, other immunosuppressives Notes: Disease severity referred to that of rheumatoid arthritis or systemic lupus erythematosus. Other immunosuppressives included other synthetic and biologic disease-modifying antirheumatic drugs and oral corticosteroids. Other comorbidities included hypertension, diabetes severity, heart disease, liver disease, respiratory disease excluding asthma, kidney disease, stroke, dementia, cancer

|                                    | Total           | No HCQ          | НСQ            |
|------------------------------------|-----------------|-----------------|----------------|
| Sample size, n                     | 167,874 (100.0) | 144,151 (100.0) | 23,723 (100.0) |
| Demographics                       |                 |                 |                |
| Age, years                         |                 |                 |                |
| Median (IQR)                       | 67 (56-76)      | 67 (56-76)      | 65 (55-73)     |
| 18-39                              | 10,088 (6.0)    | 8,957 (6.2)     | 1,131 (4.8)    |
| 40-49                              | 15,111 (9.0)    | 12,822 (8.9)    | 2,289 (9.6)    |
| 50-59                              | 30,917 (18.4)   | 26,023 (18.1)   | 4,894 (20.6)   |
| 60-69                              | 40,035 (23.8)   | 33,464 (23.2)   | 6,571 (27.7)   |
| 70-79                              | 44,491 (26.5)   | 38,279 (26.6)   | 6,212 (26.2)   |
| ≥80                                | 27,232 (16.2)   | 24,606 (17.1)   | 2,626 (11.1)   |
| Sex                                |                 |                 |                |
| Female                             | 116,406 (69.3)  | 99,238 (68.8)   | 17,168 (72.4)  |
| Male                               | 51,468 (30.7)   | 44,913 (31.2)   | 6,555 (27.6)   |
| Ethnicity                          |                 |                 |                |
| White                              | 115,869 (69.0)  | 99,746 (69.2)   | 16,123 (68.0)  |
| South Asian                        | 8,511 (5.1)     | 7,081 (4.9)     | 1,430 (6.0)    |
| Black                              | 1,981 (1.2)     | 1,688 (1.2)     | 293 (1.2)      |
| Mixed                              | 881 (0.5)       | 724 (0.5)       | 157 (0.7)      |
| Other                              | 1,354 (0.8)     | 1,168 (0.8)     | 186 (0.8)      |
| Missing                            | 39,278 (23.4)   | 33,744 (23.4)   | 5,534 (23.3)   |
| Index of multiple deprivation      |                 |                 |                |
| 1 (least deprived)                 | 33,439 (19.9)   | 28,787 (20.0)   | 4,652 (19.6)   |
| 2                                  | 33,922 (20.2)   | 29,199 (20.3)   | 4,723 (19.9)   |
| 3                                  | 33,702 (20.1)   | 28,860 (20.0)   | 4,842 (20.4)   |
| 4                                  | 33,311 (19.8)   | 28,614 (19.9)   | 4,697 (19.8)   |
| 5 (most deprived)                  | 33,500 (20.0)   | 28,691 (19.9)   | 4,809 (20.3)   |
| Residence type                     |                 |                 |                |
| Rural                              | 39,577 (23.6)   | 33,829 (23.5)   | 5,748 (24.2)   |
| Urban                              | 128,297 (76.4)  | 110,322 (76.5)  | 17,975 (75.8)  |
| Body mass index, kg/m <sup>2</sup> |                 |                 |                |
| <18.5                              | 3,721 (2.2)     | 3,205 (2.2)     | 516 (2.2)      |
| 18.5-24.9                          | 48,185 (28.7)   | 41,443 (28.7)   | 6,742 (28.4)   |
| 25-29.9                            | 54,164 (32.3)   | 46,823 (32.5)   | 7,341 (30.9)   |
| 30-34.9                            | 31,102 (18.5)   | 26,617 (18.5)   | 4,485 (18.9)   |
| 35-39.9                            | 13,159 (7.8)    | 11,103 (7.7)    | 2,056 (8.7)    |
| ≥40                                | 6,778 (4.0)     | 5,521 (3.8)     | 1,257 (5.3)    |
| Missing                            | 10,765 (6.4)    | 9,439 (6.5)     | 1,326 (5.6)    |
| Smoking status                     |                 |                 |                |

**eTable 1.** Demographic and clinical characteristics of 167,874 patients with rheumatoid arthritis

| Never                                  | 63,068 (37.6)  | 54,640 (37.9)          | 8,428 (35.5)  |
|--|----------------|------------------------|---------------|
| Former                                 | 81,304 (48.4)  | 69,376 (48.1)          | 11,928 (50.3) |
| Current                                | 23,023 (13.7)  | 19 <i>,</i> 696 (13.7) | 3,327 (14.0)  |
| Missing                                | 479 (0.3)      | 439 (0.3)              | 40 (0.2)      |
| Clinical conditions                    |                |                        |               |
| Diabetes                               |                |                        |               |
| No diabetes                            | 136,690 (81.4) | 116,885 (81.1)         | 19,805 (83.5) |
| Diabetes, HbA1c <7.5%                  | 20,294 (12.1)  | 17,659 (12.3)          | 2,635 (11.1)  |
| Diabetes, HbA1c ≥7.5%                  | 8,171 (4.9)    | 7,261 (5.0)            | 910 (3.8)     |
| Diabetes, missing HbA1c                | 2,719 (1.6)    | 2,346 (1.6)            | 373 (1.6)     |
| eGFR, ml/min/1.73m <sup>2</sup>        |                |                        |               |
| ≥60                                    | 117,522 (70.0) | 98,630 (68.4)          | 18,892 (79.6) |
| 30-59                                  | 21,998 (13.1)  | 19,189 (13.3)          | 2,809 (11.8)  |
| <30                                    | 1,622 (1.0)    | 1,445 (1.0)            | 177 (0.7)     |
| Missing                                | 26,732 (15.9)  | 24,887 (17.3)          | 1,845 (7.8)   |
| Heart disease                          | 27,249 (16.2)  | 23,708 (16.4)          | 3,541 (14.9)  |
| Liver disease                          | 2,111 (1.3)    | 1,787 (1.2)            | 324 (1.4)     |
| Respiratory disease (excluding asthma) | 23,925 (14.3)  | 20,083 (13.9)          | 3,842 (16.2)  |
| Neurological condition                 | 10,896 (6.5)   | 9,646 (6.7)            | 1,250 (5.3)   |
| Hypertension                           | 73,863 (44.0)  | 63,955 (44.4)          | 9,908 (41.8)  |
| Cancer                                 | 17,603 (10.5)  | 15,238 (10.6)          | 2,365 (10.0)  |
| Immunosuppression                      | 2,200 (1.3)    | 1,851 (1.3)            | 349 (1.5)     |
| Influenza vaccination 2019/20          | 108,883 (64.9) | 91,697 (63.6)          | 17,186 (72.4) |
| Other medications                      |                |                        |               |
| Other sDMARD                           | 68,490 (40.8)  | 54,401 (37.7)          | 14,089 (59.4) |
| Azithromycin                           | 850 (0.5)      | 691 (0.5)              | 159 (0.7)     |
| Oral corticosteroid                    | 28,858 (17.2)  | 23,968 (16.6)          | 4,890 (20.6)  |
| NSAID                                  | 30,606 (18.2)  | 25,042 (17.4)          | 5,564 (23.5)  |

*Abbreviations:* IQR, interquartile range; HbA1c, glycated haemoglobin; eGFR, estimated glomerular filtration rate; sDMARD, synthetic disease-modifying antirheumatic drug; NSAID, non-steroidal anti-inflammatory drug

|                                    | Total          | No HCO         | НСО           |
|------------------------------------|----------------|----------------|---------------|
| Sample size, n                     | 26,763 (100.0) | 19,917 (100.0) | 6,846 (100.0) |
| Demographics                       | , , , ,        | , , ,          | , , , ,       |
| Age, vears                         |                |                |               |
| Median (IOR)                       | 58 (47-70)     | 60 (48-71)     | 55 (44-66)    |
| 18-39                              | 3.621 (13.5)   | 2.476 (12.4)   | 1.145 (16.7)  |
| 40-49                              | 4,327 (16.2)   | 3,007 (15.1)   | 1,320 (19.3)  |
| 50-59                              | 6,169 (23.1)   | 4,434 (22.3)   | 1,735 (25.3)  |
| 60-69                              | 5,664 (21.2)   | 4,262 (21.4)   | 1,402 (20.5)  |
| 70-79                              | 4,747 (17.7)   | 3,811 (19.1)   | 936 (13.7)    |
| ≥80                                | 2,235 (8.4)    | 1,927 (9.7)    | 308 (4.5)     |
| Sex                                |                |                | . ,           |
| Female                             | 22,034 (82.3)  | 15,868 (79.7)  | 6,166 (90.1)  |
| Male                               | 4,729 (17.7)   | 4,049 (20.3)   | 680 (9.9)     |
| Ethnicity                          | , , ,          | , , ,          | ( )           |
| White                              | 16,828 (62.9)  | 12,621 (63.4)  | 4,207 (61.5)  |
| South Asian                        | 1,987 (7.4)    | 1,421 (7.1)    | 566 (8.3)     |
| Black                              | 1,016 (3.8)    | 737 (3.7)      | 279 (4.1)     |
| Mixed                              | 398 (1.5)      | 281 (1.4)      | 117 (1.7)     |
| Other                              | 484 (1.8)      | 340 (1.7)      | 144 (2.1)     |
| Missing                            | 6,050 (22.6)   | 4,517 (22.7)   | 1,533 (22.4)  |
| Index of multiple deprivation      |                |                |               |
| 1 (least deprived)                 | 5,529 (20.7)   | 4,167 (20.9)   | 1,362 (19.9)  |
| 2                                  | 5,515 (20.6)   | 4,152 (20.8)   | 1,363 (19.9)  |
| 3                                  | 5,240 (19.6)   | 3,940 (19.8)   | 1,300 (19.0)  |
| 4                                  | 5,166 (19.3)   | 3,788 (19.0)   | 1,378 (20.1)  |
| 5 (most deprived)                  | 5,313 (19.9)   | 3,870 (19.4)   | 1,443 (21.1)  |
| Residence type                     |                |                |               |
| Rural                              | 6,079 (22.7)   | 4,476 (22.5)   | 1,603 (23.4)  |
| Urban                              | 20,684 (77.3)  | 15,441 (77.5)  | 5,243 (76.6)  |
| Body mass index, kg/m <sup>2</sup> |                |                |               |
| <18.5                              | 651 (2.4)      | 487 (2.4)      | 164 (2.4)     |
| 18.5-24.9                          | 8,796 (32.9)   | 6,608 (33.2)   | 2,188 (32.0)  |
| 25-29.9                            | 7,706 (28.8)   | 5,844 (29.3)   | 1,862 (27.2)  |
| 30-34.9                            | 4,213 (15.7)   | 3,035 (15.2)   | 1,178 (17.2)  |
| 35-39.9                            | 1,840 (6.9)    | 1,269 (6.4)    | 571 (8.3)     |
| ≥40                                | 949 (3.5)      | 635 (3.2)      | 314 (4.6)     |
| Missing                            | 2,608 (9.7)    | 2,039 (10.2)   | 569 (8.3)     |
| Smoking status                     |                |                |               |

**eTable 2.** Demographic and clinical characteristics of 26,763 patients with systemic lupus erythematosus (SLE)

| Never                                  | 11,116 (41.5) | 8,065 (40.5)  | 3,051 (44.6)          |
|--|---------------|---------------|-----------------------|
| Former                                 | 11,128 (41.6) | 8,364 (42.0)  | 2,764 (40.4)          |
| Current                                | 4,388 (16.4)  | 3,383 (17.0)  | 1,005 (14.7)          |
| Missing                                | 131 (0.5)     | 105 (0.5)     | 26 (0.4)              |
| Clinical conditions                    |               |               |                       |
| Diabetes                               |               |               |                       |
| No diabetes                            | 23,140 (86.5) | 17,069 (85.7) | 6,071 (88.7)          |
| Diabetes, HbA1c <7.5%                  | 2,419 (9.0)   | 1,901 (9.5)   | 518 (7.6)             |
| Diabetes, HbA1c ≥7.5%                  | 827 (3.1)     | 669 (3.4)     | 158 (2.3)             |
| Diabetes, missing HbA1c                | 377 (1.4)     | 278 (1.4)     | 99 (1.4)              |
| eGFR, ml/min/1.73m <sup>2</sup>        |               |               |                       |
| ≥60                                    | 15,849 (59.2) | 10,976 (55.1) | 4,873 (71.2)          |
| 30-59                                  | 2,530 (9.5)   | 1,964 (9.9)   | 566 (8.3)             |
| <30                                    | 322 (1.2)     | 253 (1.3)     | 69 (1.0)              |
| Missing                                | 8,062 (30.1)  | 6,724 (33.8)  | 1,338 (19.5)          |
| Heart disease                          | 3,360 (12.6)  | 2,584 (13.0)  | 776 (11.3)            |
| Liver disease                          | 607 (2.3)     | 440 (2.2)     | 167 (2.4)             |
| Respiratory disease (excluding asthma) | 2,755 (10.3)  | 2,076 (10.4)  | 679 (9.9)             |
| Neurological condition                 | 1,822 (6.8)   | 1,357 (6.8)   | 465 (6.8)             |
| Hypertension                           | 9,541 (35.6)  | 7,162 (36.0)  | 2,379 (34.8)          |
| Cancer                                 | 2,425 (9.1)   | 1,906 (9.6)   | 519 (7.6)             |
| Immunosuppression                      | 769 (2.9)     | 548 (2.8)     | 221 (3.2)             |
| Influenza vaccination 2019/20          | 13,412 (50.1) | 9,415 (47.3)  | 3 <i>,</i> 997 (58.4) |
| Other medications                      |               |               |                       |
| Other sDMARD                           | 3,033 (11.3)  | 1,379 (6.9)   | 1,654 (24.2)          |
| Azithromycin                           | 98 (0.4)      | 60 (0.3)      | 38 (0.6)              |
| Oral corticosteroid                    | 4,819 (18.0)  | 2,824 (14.2)  | 1,995 (29.1)          |
| NSAID                                  | 2,750 (10.3)  | 1,644 (8.3)   | 1,106 (16.2)          |

*Abbreviations:* IQR, interquartile range; HbA1c, glycated haemoglobin; eGFR, estimated glomerular filtration rate; sDMARD, synthetic disease-modifying antirheumatic drug; NSAID, non-steroidal anti-inflammatory drug

|                     |            | DAG-Informed Adjustment |                                       |         |
|---------------------|------------|-------------------------|---------------------------------------|---------|
|                     | No. events | HR                      | 95% CI                                | p-value |
| Age                 |            |                         |                                       |         |
| 18-59 years         |            |                         |                                       |         |
| No HCQ              | 18 (0.0)   | 1                       | (ref)                                 | 0.78    |
| HCQ                 | 6 (0.0)    | 1.50                    | (0.59-3.79)                           |         |
| 60-69 years         |            |                         |                                       |         |
| No HCQ              | 40 (0.1)   | 1                       | (ref)                                 |         |
| HCQ                 | 10 (0.1)   | 1.17                    | (0.58-2.35)                           |         |
| 70-79 years         |            |                         |                                       |         |
| No HCQ              | 148 (0.4)  | 1                       | (ref)                                 |         |
| HCQ                 | 25 (0.3)   | 0.97                    | (0.63-1.48)                           |         |
| ≥80 years           |            |                         | . ,                                   |         |
| No HCQ              | 271 (1.0)  | 1                       | (ref)                                 |         |
| HCQ                 | 29 (1.0)   | 0.92                    | (0.62-1.35)                           |         |
| Other sDMARD        |            |                         | , , , , , , , , , , , , , , , , , , , |         |
| No                  |            |                         |                                       |         |
| No HCQ              | 311 (0.3)  | 1                       | (ref)                                 | 0.22    |
| НСО                 | 41 (0.3)   | 1.14                    | (0.82-1.59)                           |         |
| Yes                 |            |                         | (0.02 2.00)                           |         |
| No HCQ              | 166 (0.3)  | 1                       | (ref)                                 |         |
| НСО                 | 29 (0.2)   | 0.83                    | (0.56-1.24)                           |         |
| Oral corticosteroid |            |                         | , , , , , , , , , , , , , , , , , , , |         |
| No                  |            |                         |                                       |         |
| No HCQ              | 296 (0.2)  | 1                       | (ref)                                 | 0.97    |
| НСО                 | 38 (0.2)   | 1.00                    | (0.71-1.41)                           |         |
| Yes                 |            |                         |                                       |         |
| No HCQ              | 181 (0.7)  | 1                       | (ref)                                 |         |
| НСО                 | 32 (0.5)   | 0.99                    | (0.68-1.45)                           |         |
| NSAID               | - ()       |                         | (                                     |         |
| No                  |            |                         |                                       |         |
| No HCO              | 443 (0 3)  | 1                       | (ref)                                 | 0 11    |
| НСО                 | 62 (0.3)   | 0.98                    | (0.75-1.29)                           | 0.111   |
| Yes                 | 02 (0.0)   | 0.00                    | (01/0 1120)                           |         |
| No HCO              | 34 (0.1)   | 1                       | (ref)                                 |         |
| HCQ                 | 8 (0.1)    | 1.18                    | (0.55-2.56)                           |         |

eTable 3. Interactions with HCQ use on the risk of COVID-19 mortality

*Abbreviations:* HCQ, hydroxychloroquine; COVID-19, coronavirus disease 2019; DAG, directed acyclic graph; CI, confidence interval; sDMARD, synthetic disease-modifying antirheumatic drug; STP, Sustainability and Transformation Partnership (a National Health Service administrative region)

Notes: DAG-Informed models adjusted for age, sex, ethnicity, other immunosuppressives (other sDMARDs, oral corticosteroids) and stratified by population (i.e., RA or SLE) and STP of the patient's general practice to allow for geographical differences in baseline hazards.

|   |            | DAG-Informed Adjustment |             |
|---|------------|-------------------------|-------------|
|   | No. events | HR                      | 95% CI      |
| Ethnicity adjustments                     |            |                         |             |
| All patients, without adjustment for eth  | nicity     |                         |             |
| No HCQ                                    | 477 (0.3)  | 1                       | (ref)       |
| HCQ                                       | 70 (0.2)   | 1.03                    | (0.80-1.33) |
| Exclude individuals with missing ethnicit | y          |                         |             |
| No HCQ                                    | 358 (0.3)  | 1                       | (ref)       |
| HCQ                                       | 48 (0.2)   | 0.94                    | (0.69-1.28) |
| Additional adjustment for ethnicity       |            |                         |             |
| No HCQ                                    | 358 (0.3)  | 1                       | (ref)       |
| HCQ                                       | 48 (0.2)   | 0.94                    | (0.69-1.27) |
|   |            |                         |             |
| Shorten exposure ascertainment to 3 m     | onths      |                         |             |
| No HCQ                                    | 477 (0.3)  | 1                       | (ref)       |
| HCQ                                       | 70 (0.2)   | 1.03                    | (0.80-1.33) |
| Population adjustment                     |            |                         |             |
| Change from stratifying to indicator vari | able       |                         |             |
| No HCQ                                    | 477 (0.3)  | 1                       | (ref)       |
| HCQ                                       | 70 (0.2)   | 0.94                    | (0.69-1.27) |
|   |            |                         |             |
| Model populations separately              |            |                         |             |
| Rheumatoid arthritis (RA)                 |            |                         |             |
| No HCQ                                    | 449 (0.3)  | 1                       | (ref)       |
| HCQ                                       | 60 (0.3)   | 0.98                    | (0.75-1.29) |
| Systemic lupus erythematosus (SLE)        |            |                         |             |
| No HCQ                                    | 28 (0.1)   | 1                       | (ref)       |
| HCQ                                       | 10 (0.1)   | 1.64                    | (0.68-3.97) |

**eTable 4.** Sensitivity analyses of the association between HCQ use and the risk of COVID-19 mortality

*Abbreviations:* HCQ, hydroxychloroquine; COVID-19, coronavirus disease 2019; DAG, directed acyclic graph; CI, confidence interval; sDMARD, synthetic disease-modifying antirheumatic drug; STP, Sustainability and Transformation Partnership (a National Health Service administrative region)

Notes: DAG-Informed models adjusted for age, sex, ethnicity, other immunosuppressives (other sDMARDs, oral corticosteroids) and stratified by population (i.e., RA or SLE) and STP of the patient's general practice to allow for geographical differences in baseline hazards.

| biologic DiviANDS and associations with COVID-19 monality |  |   |                     |                     |                     |
|---|--|---|---------------------|---------------------|---------------------|
|   |  | Association between bDMARD and COVID-19 mortality |                     |                     |                     |
| Prevalence of<br>bDMARD among<br>exposed                  | Prevalence of<br>bDMARD among<br>unexposed | HR 0.80   | HR 0.90             | HR 1.10             | HR 1.20             |
| 18%   | 21%  | 1.02<br>(0.79-1.32)                               | 1.03<br>(0.79-1.32) | 1.03<br>(0.80-1.33) | 1.03<br>(0.80-1.34) |
| 3%  | 30%  | 0.97<br>(0.75-1.26)                               | 1.00<br>(0.78-1.29) | 1.06<br>(0.82-1.36) | 1.08<br>(0.84-1.40) |
| 30%   | 3%   | 1.09<br>(0.84-1.40)                               | 1.06<br>(0.82-1.36) | 1.00<br>(0.78-1.29) | 0.98<br>(0.76-1.26) |

**eTable 5.** Bias-adjusted associations using a range of estimated prevalence of biologic DMARDs and associations with COVID-19 mortality

*Abbreviations:* bDMARD, biologic disease-modifying antirheumatic drug; COVID-19, coronavirus disease 2019; HR, hazard ratio

|                                 | Stratified Cox (stcox) |             | Flexibl<br>( | e parametric<br>stpm2) |
|---------------------------------|------------------------|-------------|--------------|------------------------|
|                                 | HR                     | 95% CI      | HR           | 95% CI                 |
| COVID-19 mortality              |                        |             |              |                        |
| HCQ, yes vs. no                 | 1.03                   | (0.80-1.33) | 1.03         | (0.80-1.33)            |
| Sex, male vs. female            | 1.46                   | (1.23-1.74) | 1.45         | (1.22-1.72)            |
| Age, spline 1                   | 1.05                   | (0.98-1.13) | 1.05         | (0.98-1.13)            |
| Age, spline 2                   | 1.08                   | (0.97-1.19) | 1.08         | (0.97-1.19)            |
| Age, spline 3                   | 0.75                   | (0.50-1.11) | 0.74         | (0.50-1.10)            |
| Other sDMARD, yes vs. no        | 0.93                   | (0.78-1.12) | 0.91         | (0.76-1.09)            |
| Oral corticosteroid, yes vs. no | 2.47                   | (2.07-2.93) | 2.45         | (2.06-2.91)            |
| Non COVID-19 mortality          |                        |             |              |                        |
| HCQ, yes vs. no                 | 1.00                   | (0.87-1.15) | 1.00         | (0.87-1.15)            |
| Sex, male vs. female            | 1.25                   | (1.14-1.37) | 1.25         | (1.14-1.37)            |
| Age, spline 1                   | 1.06                   | (1.03-1.10) | 1.06         | (1.03-1.10)            |
| Age, spline 2                   | 1.03                   | (0.98-1.09) | 1.03         | (0.98-1.09)            |
| Age, spline 3                   | 0.94                   | (0.77-1.14) | 0.94         | (0.77-1.14)            |
| Other sDMARD, yes vs. no        | 0.68                   | (0.61-0.75) | 0.68         | (0.62-0.75)            |
| Oral corticosteroid, yes vs. no | 2.03                   | (1.85-2.23) | 2.03         | (1.85-2.22)            |

**eTable 6.** Comparison of estimates between stratified Cox proportional hazards models and Royston-Parmar flexible parametric models

Note: Cox models (Stata command: stcox) were stratified on STP and RA/SLE population. Royston-Parmar flexible parametric models (Stata command: stpm2) were stratified on STP and included a binary indicator for RA/SLE population as a fixed effect.

Estimating prevalence of biologic DMARDs by exposure group for eTable 5 We applied Bayes' rule to obtain estimates of the prevalence of biologic DMARDs by exposure group.

Bayes' rule definition:

$$P(A|B) = \frac{P(B|A) P(A)}{P(B)}$$

In 2017, among 400,000 rheumatoid arthritis patients in the UK, 84,200 (21%) were treated with biologics.<sup>5</sup> Previous drug utilisation research has shown that 12% of rheumatoid arthritis patients on biologics were co-prescribed hydroxychloroquine.<sup>6</sup> In our cohort of 167,874 patients with rheumatoid arthritis, 23,723 (14%) were prescribed hydroxychloroquine.

We substituted biologics for *A* and hydroxychloroquine use for *B* in Bayes' rule.

#### Bayes' rule application:

$$P(B|HCQ) = \frac{P(HCQ|B) P(B)}{P(HCQ)}$$
$$P(B|HCQ) = \frac{0.12 \times 0.21}{0.14} = 0.18$$

By law of total probability:

$$P(B) = P(B|HCQ) P(HCQ) + P(B|HCQ) P(HCQ)$$
  

$$0.21 = 0.18 \times 0.14 + P(B|HCQ) \times 0.86$$
  

$$P(B|HCQ) = \frac{0.21 - (0.18 \times 0.14)}{0.86} = 0.21$$

Given the above assumptions, we estimated prevalence of biologic DMARDs to be 18% among hydroxychloroquine users and 21% among those not prescribed hydroxychloroquine.

We used these estimates to calculate bias-adjusted associations in quantitative bias analyses. To account for uncertainty in these estimates and any variation in prescribing practices between rheumatoid arthritis and systemic lupus erythematosus patient populations, we also examined more extreme values of prevalence (range 3-30%).

#### References

- 1. NHS Digital. Data Security and Protection Toolkit. 2020. Accessed August 11, 2020. https://digital.nhs.uk/data-and-information/looking-after-information/data-security-and-information-governance/data-security-and-protection-toolkit
- 2. NHS Digital. BETA Data Security Standards. 2020. Accessed August 11, 2020. https://digital.nhs.uk/about-nhs-digital/our-work/nhs-digital-data-and-technologystandards/framework/beta---data-security-standards
- 3. NHS Digital. ISB1523: Anonymisation Standard for Publishing Health and Social Care Data. 2020. Accessed August 11, 2020. https://digital.nhs.uk/data-and-information/information-standards/information-standards-and-data-collections-including-extractions/publications-and-notifications/standards-and-collections/isb1523-anonymisation-standard-for-publishing-health-and-social-care-data
- Secretary of State for Health-UK Government. Coronavirus (COVID-19): notification to organisations to share information. 2020. Accessed August 11, 2020. https://www.gov.uk/government/publications/coronavirus-covid-19-notification-of-data-controllersto-share-information
- 5. Kim H. The Roles of Biosimilars in Patient Access to Biologics in UK. Accessed August 11, 2020. https://www.england.nhs.uk/expo/wp-content/uploads/sites/18/2018/09/12.30-Improving-patient-care-with-biologics-in-the-management-of-RA-Celltrion-Healthcare-P2C.pdf
- 6. Choy E, Taylor P, McAuliffe S, Roberts K, Sargeant I. Variation in the use of biologics in the management of rheumatoid arthritis across the UK. *Curr Med Res Opin.* 2012;28(10):1733-1741.